undamentalytics Newsletter
Sign in

Congress: members

Steve Cohen

Backtest from 3 Sept 2015 to 2 Nov 2026 · weekly · hypothetical

Watch this strategy
Return a year
+8.4%
S&P 500 +14.8%
Last 12 months
+16.0%
S&P 500 +12.1%
Sharpe ratio
0.41
S&P 500 0.77
Biggest drop
−39.5%
S&P 500 −31.8%
$10.0k$20.0k$40.0k 201520172019202120232025 $46.5k$24.5k
Steve CohenS&P 500 $10,000 in Steve Cohen from 3 Sept 2015 against the S&P 500 (total return) over the same dates, marked weekly, log scale. Hypothetical: before taxes and trading costs.

About

Mirrors the disclosed stock holdings of Rep. Steve Cohen (Democrat, TN) and family. It buys on the first trading day after each report is filed, sized by the middle of the value band reported, starts from the holdings listed in the member's annual disclosure report once that report is public, and holds each position until a sale is reported. Call options count as the stock until they expire. Members often report weeks or months late, so this is what a follower could actually have done.

Steve Cohen's trades →

Key statistics

MeasureStrategyS&P 500
Return a year (compound)+8.4%+14.8%
Total return+145%+365%
Last 12 months+16.0%+12.1%
Last 3 months+9.2%—
Last month+10.2%—
This year so far+11.5%—
Volatility a year17.5%16.7%
Sharpe ratio0.410.77
Biggest drop−39.5%−31.8%
Beta to the S&P 5000.891.00
Alpha a year (t-statistic)−4.2% (−1.49)—
Share of weeks up55%—

Sharpe ratio uses returns above the 3-month Treasury bill rate. Alpha is the yearly return left after allowing for the strategy's exposure to the S&P 500 (CAPM); a t-statistic below about 2 means it cannot be told apart from luck. 76 reported trades were copied.

Insights

CompanyWeightHeld sinceReturn since
BRK.B16.5%16 Aug 2021+91.9%
MSFT11.0%16 Aug 2021+83.3%
IBM10.8%16 Aug 2021+126.2%
XOM7.3%16 Aug 2021+285.3%
AMGN6.9%17 May 2016+321.6%
FDX6.6%16 Aug 2021+56.1%
MAR6.4%16 Aug 2021+224.5%
NOC4.7%17 May 2016+207.6%
AZO4.5%16 Aug 2021+98.7%
FHN4.1%16 Aug 2021+74.7%
LLY3.8%16 Aug 2021+444.8%
CVX3.1%16 Aug 2021+180.6%
RTX2.3%16 May 2024+101.5%
MAA1.8%16 Aug 2021−23.5%
TM1.6%16 Aug 2021+21.2%
MRK1.3%17 May 2016+295.4%
KO1.2%16 Aug 2021+94.6%
T1.0%16 Aug 2021+38.1%
RF1.0%16 Aug 2021+76.5%
GSK0.9%17 May 2016+87.5%
PEP0.9%16 Aug 2021+5.2%
DIS0.9%16 Aug 2021−34.5%
CMCSA0.8%16 Aug 2021−48.9%
SLB0.3%16 Aug 2021+113.1%
HLN0.2%11 Aug 2023+7.3%
PeriodReturn a yearS&P 500SharpeS&P 500Biggest dropBetaAlpha (t)
Whole backtest3 Sept 2015 to 2 Nov 2026+8.4%+14.8%0.410.77−39.5%0.89−4.2% (−1.49)
2018 onwards5 Jan 2018 to 2 Nov 2026+7.6%+13.9%0.340.66−39.5%0.89−4.2% (−1.30)
Last three years3 Nov 2023 to 2 Nov 2026+18.4%+21.8%1.041.16−10.2%0.61+3.3% (0.60)
Last year7 Nov 2025 to 2 Nov 2026+14.9%+14.2%0.830.84−8.1%0.41+6.7% (0.55)
DateCompanyAction
16 May 2024RTXBought
11 Aug 2023HLNBought
15 Aug 2022OGNBought
15 Aug 2022KDBought
16 Aug 2021XOMBought
16 Aug 2021TMBought
16 Aug 2021TBought
16 Aug 2021SLBBought
16 Aug 2021RFBought
16 Aug 2021PEPBought
16 Aug 2021MSFTBought
16 Aug 2021MARBought
16 Aug 2021MAABought
16 Aug 2021LLYBought
16 Aug 2021KOBought
16 Aug 2021IBMBought
16 Aug 2021HSTBought
16 Aug 2021FHNBought
16 Aug 2021FDXBought
16 Aug 2021EBSBought
16 Aug 2021DISBought
16 Aug 2021CVXBought
16 Aug 2021CMCSABought
16 Aug 2021BRK.BBought
16 Aug 2021AZOBought

Dated on the first trading day after the report was filed, when a follower could have acted.

DateCompanyAction
18 May 2026OGNSold
18 May 2026GSSold
27 Jan 2026FLRSold
13 Jan 2025HSTSold
13 Jan 2025EBSSold
5 Jan 2024KDSold
16 Aug 2021WYSold
16 Aug 2021RIGSold
16 Aug 2021GESold
16 Aug 2021ENBSold
16 Aug 2021DUKSold
16 Aug 2021CHTRSold
16 Aug 2021CCLSold
16 Aug 2021APVOSold
16 Aug 2021AALSold
26 May 2020PEPSold
26 May 2020MARSold
26 May 2020MAASold
26 May 2020FDXSold
26 May 2020CMCSASold
26 May 2020BASold
26 May 2020AZOSold
23 Apr 2020XOMSold
23 Apr 2020TMSold
23 Apr 2020SLBSold

Dated on the first trading day after the report was filed, when a follower could have acted.

Backtests are hypothetical and use today's listed companies only, which flatters results. Past performance does not predict future returns. This is research, not investment advice. How we backtest